

CSE Symbol: IME
OTC PINK Symbol: IMEXF
Frankfurt/Stuttgart Stock Exchanges: DPD2

NR-2016-IME-19

Ken Daignault Joins Imagin Medical's Board of Directors

Imagin Medical is the developer of the ultrasensitive i/Blue Imaging System that will establish a new standard of care for urologists in detecting bladder cancer through endoscopes.

Vancouver, B.C. and Boston, MA, September 29, 2016 – Imagin Medical (CSE: IME) (OTC PINK: IMEXF) (Frankfurt/Stuttgart Stock Exchanges: DPD2) (the “Company”) announced today that Ken Daignault has joined Imagin’s Board of Directors.

The addition of Mr. Daignault to Imagin Medical’s Board of Directors demonstrates its continued transition from mining exploration to a medical technology company. With almost 30 years of experience in the medical device field, specifically in urology, Ken will be a valued member of the Board of Directors. Ken has held senior level management positions in two major medical device companies, most recently with Boston Scientific as Director of R & D, Urology and previously as a Senior R&D Director with CR Bard, one of the world’s largest urology companies. He has been involved in all aspects of the medical device business from product development and the design of protocols and procedures for bench and animal pre-clinical testing to building long-term strategies for multiple-product portfolios at various stages of development. Ken has strong relationships within the urology field and with key medical institutions, as well as a track record of bringing products from concept through successful product launch.

“With his business background, knowledge and experience in the medical device field, Ken will be a great addition to our Board.” said Jim Hutchens, Imagin President and CEO. “Imagin will benefit from his product development as well as his clinical experience.”

About Imagin Medical

Imagin Medical is developing imaging solutions for the early detection of cancer through the use of endoscopes. The Company believes it will radically improve the way physicians detect cancer. Imagin’s initial target market is bladder cancer, a major cancer worldwide, the sixth most prevalent in the U.S., and the most costly cancer to treat due to a greater than 50% recurrence rate. Developed at the Lawrence Livermore National Laboratory, this advanced, ultrasensitive imaging technology is based upon improved optical designs and advanced light sensors. Learn more at www.imaginmedical.com.

ON BEHALF OF THE BOARD:

Jim Hutchens,

President & CEO

For further information, contact:

Bill Galine, Investor Relations

Telephone: (775) 737-3292

Email: billgaline@gmail.com

Information set forth in this news release contains forward-looking statements. These statements reflect management's current estimates, beliefs, intentions and expectations; they are not guarantees of future performance. The Company cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information. The CSE has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.